SENS 111

Drug Profile

SENS 111

Alternative Names: Histamine H4 receptor antagonist - Palau Pharma; SENS111; UR-63325

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Palau Pharma
  • Developer Palau Pharma; Sensorion
  • Class Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Vertigo
  • Preclinical Tinnitus
  • No development reported Asthma; Seasonal allergic rhinitis

Most Recent Events

  • 23 Mar 2017 Phase-II clinical trials in Vertigo in Czech Republic (PO) (EudraCT2016-003927-45)
  • 01 Sep 2016 The US FDA approves IND application for a phase II trial in Vertigo in USA and Europe
  • 04 Sep 2015 No recent reports on development identified - Phase-I for Asthma and Seasonal allergic rhinitis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top